JP2021515005A - 標識オキシトシンならびに製造および使用の方法 - Google Patents

標識オキシトシンならびに製造および使用の方法 Download PDF

Info

Publication number
JP2021515005A
JP2021515005A JP2020545532A JP2020545532A JP2021515005A JP 2021515005 A JP2021515005 A JP 2021515005A JP 2020545532 A JP2020545532 A JP 2020545532A JP 2020545532 A JP2020545532 A JP 2020545532A JP 2021515005 A JP2021515005 A JP 2021515005A
Authority
JP
Japan
Prior art keywords
oxytocin
oxytocin peptide
labeled
peptide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020545532A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019169342A5 (https=
JP2021515005A5 (https=
Inventor
ステーン ヤコブセン，
ステーン ヤコブセン，
ミカエル ヴィンターダール，
ミカエル ヴィンターダール，
エリク ホルム ニールセン，
エリク ホルム ニールセン，
デイビッド シー． ヨーマンズ，
デイビッド シー． ヨーマンズ，
カーソン，　ディーン
ディーン カーソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarhus Universitet
Original Assignee
Aarhus Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aarhus Universitet filed Critical Aarhus Universitet
Publication of JP2021515005A publication Critical patent/JP2021515005A/ja
Publication of JPWO2019169342A5 publication Critical patent/JPWO2019169342A5/ja
Publication of JP2021515005A5 publication Critical patent/JP2021515005A5/ja
Priority to JP2024009405A priority Critical patent/JP2024038482A/ja
Priority to JP2025230634A priority patent/JP2026035830A/ja
Priority to JP2025230635A priority patent/JP2026035831A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/084—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being oxytocin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
JP2020545532A 2018-03-01 2019-03-01 標識オキシトシンならびに製造および使用の方法 Pending JP2021515005A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2024009405A JP2024038482A (ja) 2018-03-01 2024-01-25 標識オキシトシンならびに製造および使用の方法
JP2025230634A JP2026035830A (ja) 2018-03-01 2025-12-04 標識オキシトシンならびに製造および使用の方法
JP2025230635A JP2026035831A (ja) 2018-03-01 2025-12-04 標識オキシトシンならびに製造および使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637187P 2018-03-01 2018-03-01
US62/637,187 2018-03-01
PCT/US2019/020419 WO2019169342A1 (en) 2018-03-01 2019-03-01 Labeled oxytocin and method of manufacture and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024009405A Division JP2024038482A (ja) 2018-03-01 2024-01-25 標識オキシトシンならびに製造および使用の方法

Publications (3)

Publication Number Publication Date
JP2021515005A true JP2021515005A (ja) 2021-06-17
JPWO2019169342A5 JPWO2019169342A5 (https=) 2022-03-07
JP2021515005A5 JP2021515005A5 (https=) 2022-03-07

Family

ID=65763911

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020545532A Pending JP2021515005A (ja) 2018-03-01 2019-03-01 標識オキシトシンならびに製造および使用の方法
JP2024009405A Withdrawn JP2024038482A (ja) 2018-03-01 2024-01-25 標識オキシトシンならびに製造および使用の方法
JP2025230635A Pending JP2026035831A (ja) 2018-03-01 2025-12-04 標識オキシトシンならびに製造および使用の方法
JP2025230634A Pending JP2026035830A (ja) 2018-03-01 2025-12-04 標識オキシトシンならびに製造および使用の方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2024009405A Withdrawn JP2024038482A (ja) 2018-03-01 2024-01-25 標識オキシトシンならびに製造および使用の方法
JP2025230635A Pending JP2026035831A (ja) 2018-03-01 2025-12-04 標識オキシトシンならびに製造および使用の方法
JP2025230634A Pending JP2026035830A (ja) 2018-03-01 2025-12-04 標識オキシトシンならびに製造および使用の方法

Country Status (4)

Country Link
US (2) US11970554B2 (https=)
EP (1) EP3759121A1 (https=)
JP (4) JP2021515005A (https=)
WO (1) WO2019169342A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3759121A1 (en) * 2018-03-01 2021-01-06 Trigemina, Inc. Labeled oxytocin and method of manufacture and use
US11631208B1 (en) * 2021-12-22 2023-04-18 RealizeMD Ltd. Systems and methods for generating clinically relevant images that preserve physical attributes of humans while protecting personal identity
US11935238B2 (en) * 2021-12-22 2024-03-19 RealizeMD Ltd. Systems and methods for generating clinically relevant images that preserve physical attributes of humans while protecting personal identity
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004161664A (ja) * 2002-11-13 2004-06-10 Fancl Corp プロポリス組成物
JP2007526300A (ja) * 2004-03-04 2007-09-13 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
JP2008514588A (ja) * 2004-09-29 2008-05-08 ジーイー・ヘルスケア・アクスイェ・セルスカプ ｕＰＡＲターゲティング造影剤
JP2010085108A (ja) * 2008-09-29 2010-04-15 Nano Factory:Kk 生体光イメージング用プローブ
US20100311655A1 (en) * 2007-06-07 2010-12-09 Mdrna, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
JP2012523403A (ja) * 2009-04-10 2012-10-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 変性病変の診断のためのリガンドとしてのフコイダン
JP2013521233A (ja) * 2010-02-25 2013-06-10 ヤンセン アルツハイマー イミュノセラピー Ａβを標的とする免疫療法のＰＥＴモニタリング
JP2013230986A (ja) * 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
JP2016114573A (ja) * 2014-12-18 2016-06-23 国立大学法人金沢大学 オキシトシン検出のためのサンプルの前処理方法
WO2017096036A1 (en) * 2015-12-02 2017-06-08 The Regents Of The University Of Michigan Her2 peptide regents and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1936364A (en) 1930-08-22 1933-11-21 Pfizer Charles & Co Citrate solutions
US2260004A (en) 1939-11-03 1941-10-21 Pfizer Charles & Co Stable soluble magnesium acid citrate
US2938891A (en) 1956-03-30 1960-05-31 Roussel Uclaf Method of making oxytocin and intermediates thereof
US3076797A (en) 1957-07-22 1963-02-05 Roussel Uclaf Process of producing oxytocin and intermediates obtained thereby
DE19627228A1 (de) 1996-07-05 1998-01-08 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
WO2004062563A2 (en) * 2003-01-16 2004-07-29 Université de Lausanne Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders
GB0319119D0 (en) 2003-08-14 2003-09-17 Optinose As Delivery devices
US20130130985A1 (en) 2010-04-01 2013-05-23 Paul Alewood Oxytocin peptide analogues
JO3400B1 (ar) 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
SG11201705591PA (en) 2015-01-07 2017-08-30 Trigemina Inc Magnesium-containing oxytocin formulations and methods of use
EP3759121A1 (en) 2018-03-01 2021-01-06 Trigemina, Inc. Labeled oxytocin and method of manufacture and use

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004161664A (ja) * 2002-11-13 2004-06-10 Fancl Corp プロポリス組成物
JP2007526300A (ja) * 2004-03-04 2007-09-13 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
JP2008514588A (ja) * 2004-09-29 2008-05-08 ジーイー・ヘルスケア・アクスイェ・セルスカプ ｕＰＡＲターゲティング造影剤
US20100311655A1 (en) * 2007-06-07 2010-12-09 Mdrna, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
JP2010085108A (ja) * 2008-09-29 2010-04-15 Nano Factory:Kk 生体光イメージング用プローブ
JP2012523403A (ja) * 2009-04-10 2012-10-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 変性病変の診断のためのリガンドとしてのフコイダン
JP2013521233A (ja) * 2010-02-25 2013-06-10 ヤンセン アルツハイマー イミュノセラピー Ａβを標的とする免疫療法のＰＥＴモニタリング
JP2013230986A (ja) * 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
JP2016114573A (ja) * 2014-12-18 2016-06-23 国立大学法人金沢大学 オキシトシン検出のためのサンプルの前処理方法
WO2017096036A1 (en) * 2015-12-02 2017-06-08 The Regents Of The University Of Michigan Her2 peptide regents and methods

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AMINO ACIDS, vol. 29, JPN6023001562, 2005, pages 151 - 160, ISSN: 0005303722 *
CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 39, no. 10, JPN6023001563, 1991, pages 2734 - 2736, ISSN: 0005303723 *
JAPANESE JOURNAL OF MEDICAL PHYSICS, vol. 35, no. 1, JPN6024014586, 2015, pages 2 - 9, ISSN: 0005303726 *
JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 45, JPN6023039591, 2002, pages 217 - 229, ISSN: 0005303725 *
NUCLEAR MEDICINE AND BIOLOGY, vol. 19, no. 4, JPN6023001564, 1992, pages 455 - 460, ISSN: 0005303724 *
PEPTIDES, vol. 30, JPN6023001561, 2009, pages 1276 - 1281, ISSN: 0005303721 *

Also Published As

Publication number Publication date
US20210002331A1 (en) 2021-01-07
US11970554B2 (en) 2024-04-30
JP2026035831A (ja) 2026-03-04
JP2026035830A (ja) 2026-03-04
US20240301004A1 (en) 2024-09-12
WO2019169342A1 (en) 2019-09-06
EP3759121A1 (en) 2021-01-06
JP2024038482A (ja) 2024-03-19
US12466855B2 (en) 2025-11-11

Similar Documents

Publication Publication Date Title
US12466855B2 (en) Labeled oxytocin and method of manufacture and use
JP2021193091A (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
AU2020286221B2 (en) Magnesium-containing oxytocin formulations and methods of use
CN108947843A (zh) 前列环素化合物、其组合物及使用方法
Al-Ghananeem et al. Gamma scintigraphy for testing bioequivalence: a case study on two cromolyn sodium nasal spray preparations
JP2022079671A (ja) マグネシウム含有オキシトシン製剤および使用の方法
CN110234335B (zh) 治疗女性性功能障碍的药物组合物和方法
HK40108141A (en) Magnesium-containing oxytocin formulations and methods of use
JP2010503623A (ja) 慢性疲労症候群及び神経変性疾患の治療用組成物及び治療方法
BR112017014545B1 (pt) Formulações de oxitocina que contém magnésio e métodos de uso
BR122024008322A2 (pt) Uso de peptídeo de oxitocina, composições e kit
BR122024008322B1 (pt) Uso de uma solução aquosa compreendendo um peptídeo de oxitocina e íons de magnésio
NZ758464A (en) Prostacyclin compounds, compositions and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230627

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240125

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240214

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240419

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251203